MedTrace Logo

Dietary Practices and Locally Advanced Lung Cancer (LUNGDIET)

NCT06068088 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2023-10-05

No results posted yet for this study

Summary

In recent years, fasting or the use of special diets (ketogenic, high protein, etc.), whether or not associated with food supplements, have increased substantially, particularly in oncology with the idea of improving for some of them, the tolerance of the proposed treatments, in particular emetogenic chemotherapy, or even to improve the prognosis. Although there are preclinical data on cell cultures and in rats, the clinical data supporting these practices are very fragmented, with few trials carried out and only including small cohorts, mainly in the context of breast cancers. It is therefore very difficult to respond objectively to patients asking the question of the merits of these changes in dietary practices in the management of their cancer.

The investigators want to carry out an inventory of the dietary practices of participating patients and their potential interest in fasting or special diets by means of a self-administered survey completed by the patient at diagnosis before treatment. This semi-quantitative self-administered survey (answers in never / sometimes / regularly / systematically) was developed by the nutrition and radiotherapy team of the Georges-Pompidou European Hospital because there was no validated medical questionnaire on fasting or the use of special diets in oncology

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

BEHAVIORAL

Self-administered survey at hospital

Self-administered survey on the food practices of the patient Completion before the beginning of chemoradiotherapy

BIOLOGICAL

Blood sample for nutritional assessment

15 ml of blood sampled during nutritional examination before the beginning and during the month following the end of chemoradiotherapy

OTHER

Consultation with nutritionist doctor and dietician

Before the beginning and during the month following the end of chemoradiotherapy Consultation of approximatively one hour

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Catherine DURDUX, MD-PhD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2024-12-31
Completion
2025-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06068088 on ClinicalTrials.gov